Home Cart Sign in  
Chemical Structure| 857890-39-2 Chemical Structure| 857890-39-2

Structure of Lenvatinib mesylate
CAS No.: 857890-39-2

Chemical Structure| 857890-39-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor, inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating potent antitumor activities.

Synonyms: E7080 mesylate; Lenvatinib (mesylate); E-7080

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lenvatinib mesylate

CAS No. :857890-39-2
Formula : C22H23ClN4O7S
M.W : 522.96
SMILES Code : O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.CS(=O)(O)=O
Synonyms :
E7080 mesylate; Lenvatinib (mesylate); E-7080
MDL No. :MFCD18633219
InChI Key :HWLFIUUAYLEFCT-UHFFFAOYSA-N
Pubchem ID :11237762

Safety of Lenvatinib mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Lenvatinib mesylate

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR1

    FGFR1, IC50:46 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
TPC-1 15 nM To investigate the mechanism of resistance to Lenvatinib in TPC-1 cells, it was found that phosphorylation of EGFR, ERK, and Akt was enhanced. PMC9459297
FRO 30 nM To investigate the mechanism of resistance to Lenvatinib in FRO cells, it was found that phosphorylation of EGFR was enhanced, but downstream signal transduction molecules were not enhanced. PMC9459297
SMMC-7721 10 μM 24 h To evaluate the effect of lenvatinib on mitochondrial membrane potential in HCC cells, results showed a significant decrease in mitochondrial membrane potential PMC7807703
HCCLM3 10 μM 24 h To evaluate the effect of lenvatinib on mitochondrial membrane potential in HCC cells, results showed a significant decrease in mitochondrial membrane potential PMC7807703
8505 C cells 2 µM Evaluate the inhibitory effect of Lenvatinib combined with BRAF inhibitor PLX4720 on the proliferation of thyroid cancer cells PMC11127897
BCPAP cells 2 µM Evaluate the inhibitory effect of Lenvatinib combined with BRAF inhibitor PLX4720 on the proliferation of thyroid cancer cells PMC11127897
HepG2 cells 80 µM 14 days To evaluate the effect of Lenvatinib on HepG2 cells, results showed that DUSP4 knockout enhanced Lenvatinib resistance. PMC9295068
Huh7 cells 20 µM 24 h To evaluate the effect of Lenvatinib on Huh7 cells, results showed that DUSP4 knockout enhanced Lenvatinib resistance. PMC9295068
Caki-1 10 μM 24 h To analyze the global gene expression profile of the B7 family, B7-H4 gene was upregulated in Caki-1 and 786-O cells. PMC9104196
786-O 10 μM 24 h To analyze the global gene expression profile of the B7 family, B7-H4 gene was upregulated in Caki-1 and 786-O cells. PMC9104196
A-498 10 μM 24 h To analyze the global gene expression profile of the B7 family, B7-H4 gene was not consistently increased in A-498 cells. PMC9104196
Hep3B/CSQT-2 MUC15 2.5 μM 7 days To evaluate the response of MUC15 overexpression to lenvatinib treatment, results showed that MUC15 overexpression enhanced sensitivity to lenvatinib. PMC8891362
Hep3B MUC15 10 μM 48 h To evaluate the effect of MUC15 overexpression on lenvatinib-induced apoptosis, results showed that MUC15 overexpression enhanced sensitivity to lenvatinib. PMC8891362
HepG2 20 or 40 μM 48 h To evaluate the effect of Lenvatinib on apoptosis and ROS levels in HepG2 cells, results showed that 20 μM Lenvatinib had limited effect on inducing apoptosis, but 40 μM significantly increased ROS levels. PMC9936410
Huh7 20 or 40 μM 48 h To evaluate the effect of Lenvatinib on apoptosis and ROS levels in Huh7 cells, results showed that 20 and 40 μM Lenvatinib significantly induced apoptosis and increased ROS levels. PMC9936410
PLC/PRF5 20 or 40 μM 48 h To evaluate the effect of Lenvatinib on apoptosis and ROS levels in PLC/PRF5 cells, results showed that 20 μM Lenvatinib had limited effect on inducing apoptosis, but 40 μM significantly increased ROS levels. PMC9936410
Hep3B 20 or 40 μM 48 h To evaluate the effect of Lenvatinib on apoptosis and ROS levels in Hep3B cells, results showed that 20 and 40 μM Lenvatinib significantly induced apoptosis and increased ROS levels. PMC9936410

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-nu nude female mice TPC-1/LR tumor xenograft model oral 6 mg/kg once daily for 9 days To investigate the inhibitory effect of Lenvatinib combined with Lapatinib on TPC-1/LR tumors, it was found that the combination significantly inhibited tumor growth. PMC9459297
Nude mice HCCLM3 xenograft model Intraperitoneal injection 5 mg/kg or 10 mg/kg Once daily until the end of the experiment To evaluate the inhibitory effect of lenvatinib alone or in combination with hydroxychloroquine on HCC growth and metastasis, results showed the best efficacy in the combination therapy group PMC7807703
nude mice 8505 C cell-derived xenograft model oral 25 mg/kg daily for 3 weeks Evaluate the anti-tumor efficacy of Lenvatinib combined with BRAF inhibitor PLX4720 in thyroid cancer xenograft model PMC11127897
Nude mice Hepatocellular carcinoma xenograft model Oral 30 mg/kg/d Once daily for 4 weeks To evaluate the effect of Lenvatinib on hepatocellular carcinoma xenograft model, results showed that DUSP4 knockout attenuated the anti-tumor effect of Lenvatinib. PMC9295068
Mice Hepa1-6 hepatoma orthotopic model Oral 10 mg/kg Once daily for two weeks To evaluate the effect of Lenvatinib on tumor angiogenesis in a hepatocellular carcinoma model, results showed that Lenvatinib inhibited tumor angiogenesis. PMC10831275
Mice HCC cell line-derived xenograft models Oral 4 mg/kg Every 5 days Knockdown of TBC1D31 significantly increases the sensitivity of HCCLM3 cells to lenvatinib PMC11516053
BALB/c nude mice Huh7 xenograft tumor model Oral 10 or 30 mg/kg Once daily for two weeks To evaluate the anti-tumor effect of Lenvatinib on Huh7 xenograft tumors, results showed that 10 and 30 mg/kg/d Lenvatinib significantly inhibited tumor growth. PMC9936410

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.56mL

1.91mL

0.96mL

19.12mL

3.82mL

1.91mL

References

 

Historical Records

Categories